Jay T. Flatley Sells 15,000 Shares of Illumina, Inc. (ILMN) Stock
Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $172.92, for a total value of $2,593,800.00. Following the completion of the sale, the director now directly owns 534,176 shares in the company, valued at approximately $92,369,713.92. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Illumina, Inc. (ILMN) traded down 0.12% on Friday, reaching $172.11. The company’s stock had a trading volume of 639,104 shares. The stock has a market capitalization of $25.13 billion, a PE ratio of 34.83 and a beta of 0.84. The stock has a 50-day moving average of $177.31 and a 200 day moving average of $165.72. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $189.48.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.64. The business had revenue of $598 million during the quarter, compared to the consensus estimate of $590.51 million. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.71 EPS. On average, equities analysts forecast that Illumina, Inc. will post $3.63 EPS for the current year.
Large investors have recently modified their holdings of the stock. Advocacy Wealth Management Services LLC bought a new stake in Illumina during the first quarter worth about $102,000. Advisory Services Network LLC bought a new stake in Illumina during the first quarter worth about $117,000. Gemmer Asset Management LLC increased its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. Patten Group Inc. increased its stake in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. Finally, Probity Advisors Inc. bought a new stake in Illumina during the first quarter worth about $204,000. Institutional investors and hedge funds own 93.77% of the company’s stock.
Several equities research analysts have recently commented on the company. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Deutsche Bank AG reissued a “hold” rating and set a $175.00 price target (up previously from $165.00) on shares of Illumina in a research note on Saturday, April 29th. Cantor Fitzgerald boosted their price target on Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 26th. Cowen and Company reissued an “outperform” rating and set a $200.00 price target on shares of Illumina in a research note on Wednesday, April 26th. Finally, Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $195.67 price target on the stock. in a research note on Tuesday, April 25th. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Illumina presently has an average rating of “Hold” and a consensus price target of $165.02.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.